Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Joo-Yong Hahn Added: 1 year ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more
Job title: Professor
Professor Keith AA Fox is Duke of Edinburgh Professor of Cardiology at the University of Edinburgh. Previous posts included Assistant Professor of Internal Medicine and Cardiology at Washington University School of Medicine, St Louis, USA; Senior Lecturer in Cardiology and Honorary Consultant Cardiologist at the University of Wales College of Medicine, Cardiff; Head of Division of Medical and… View more
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 1 year ago
Join renowned interventional cardiologists Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) for an exclusive preview of ACC.25's most significant late-breaking science.This episode of View from the Thoraxcenter delivers authoritative analysis of pivotal cardiovascular trials set to revolutionize clinical practice and research. Elevate your conference… View more
Added: 1 month ago Source:  Arrhythmia Academy
In atrial fibrillation (AF) patients post one-year drug-eluting stent (DES) implantation, non–vitamin K antagonist oral anticoagulant (NOAC) was shown to be noninferior to NOAC plus clopidogrel combination therapy.¹ Current guidelines recommend NOAC monotherapy in this patient population, but supporting evidence has been limited.²MethodologyThe ADAPT AF-DES trial was a multicenter, randomised,… View more
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 1 year ago
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the… View more
Added: 9 months ago Source:  ESC Congress 2025 Scientific Programme
ESC Congress 2025 has released twenty-eight late-breaking trials and science sessions to be presented in August 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Late-Breaking Clinical Science: Inflammation and Immune Biomarkers in Cardiovascular Risk PredictionFriday 29th August, 08:15am – 09:45am (CEST… View more